Ger­many deal with Cure­Vac and GSK primed for 80M mR­NA vac­cines a year

If there’s an­oth­er pan­dem­ic, the Ger­man gov­ern­ment is de­ter­mined not to be caught off-guard when it comes to man­u­fac­tur­ing vac­cines.

Cure­Vac and GSK have signed a deal to sup­ply Ger­many with mR­NA vac­cines for pan­dem­ic pre­pared­ness go­ing for­ward. Af­ter a set­up pe­ri­od that will last no longer than two years, the con­tract gives Ger­many’s gov­ern­ment ac­cess to the Cure­Vac man­u­fac­tur­ing ca­pac­i­ty un­til 2029.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER